Stefanie S. Jeffrey, MD
Academic Appointments
- Professor - Med Center Line, Surgery - General Surgery
- Member, Bio-X
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Stanford Women�s Cancer Center 900 Blake Wilbur Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 736-4167
- Academic Offices
Personal Information EmailAlternate Contact Research Office Tel Work (650) 723-0799Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> Breast Cancer
- General Surgery
Administrative Appointments
- Chief, Surgical Oncology Research, Stanford University (2005 - present)
- Program Director, Interdisciplinary Breast Fellowship, Stanford University (1999 - 2004)
- Chief, Breast Surgery, Stanford University (1997 - 2004)
Honors and Awards
- NASA Space Act Board Award, National Aeronautics and Space Administration (2006)
- Certificate of Special Congressional Recognition, Congresswoman Anna Eshoo, U.S. House of Representatives, California 14th Congressional District (2004)
- Stanford Fellow, Stanford University (2002-2004)
- John and Marva Warnock Faculty Scholar in Cancer Research, Stanford University (2001)
- Bessie Legarda Memorial Award, Makati Medical Center, Philippines (2000)
- Cowell Outstanding Faculty Physician Award, Stanford University (1999)
Professional Education
| Residency: | UCSF School of Medicine CA (1984) |
| Board Certification: | General Surgery, American Board of Surgery (1985) |
| Internship: | UCSF Medical Center, CA USA (1979) |
| Medical Education: | UCSF School of Medicine CA (1978) |
| M.D.: | UCSF, Medicine (1978) |
| M.A.: | Harvard University, Chemistry (1974) |
Graduate & Fellowship Program Affiliations
Community and International Work
- Microarray analysis of Korean breast cancers, Stanford University&suffix=researcher
Internet Links
Scientific Focus
Current Research Interests
For the past decade, Dr. Jeffrey's lab has performed molecular profiling of cancer cells with the goal of identifying tumor-specific therapies for the personalized treatment of cancer.
She was a member of the collaborative Stanford/Norway team that pioneered the use of DNA microarrays to measure global gene expression in solid tumors, and was involved in the development of the currently accepted classification schema for breast cancer subtypes based on gene expression profiles- such as low and high proliferation luminal, ERBB2(HER2)-overexpressing, and basal-like breast cancers (which then focused attention on triple negative breast cancers). Her laboratory refined RNA amplification techniques and developed expertise in the transcriptional profiling of tiny quantities of tumor tissue and in RNA isolation from formalin-fixed paraffin-embedded samples.
Her research currently involves extracting and profiling circulating tumor cells (CTCs) from blood and bone marrow to shed light on the metastatic process and eventually to help guide selection of appropriate therapies in individual cancer patients. To facilitate this, Dr. Jeffrey and colleagues from the School of Engineering and Genome Technology Center invented a new technology, the MagSweeper, an automated immunomagnetic separation device that isolates live rare cells from blood with high purity and minimal impact on gene expression. Her lab performs high dimensional single cell analyses on CTCs to investigate how transcriptional profiles or mutational status of different CTC populations relate to metastases and drug response, particularly for newer therapies under development or in Phase I/II clinical trials. CTCs being studied include those from patients with cancers of the breast, prostate, lung, pancreas, and liver. Dr. Jeffrey's lab is also funded to perform preclinical testing on patient-derived xenograft models to identify molecular phenotypes of breast cancer that may be targeted by epigenetic pathway inhibitors drugs, working with colleagues at University of Utah to determine how these newer therapies may be best applied to different subtypes of breast cancer.
In the past, Dr. Jeffrey worked with Dr. Robert Mah at NASA Ames Research Center to study multiplex in-vivo physiologic attributes of breast tumors in real-time using a multisensor NASA Smart Probe that she co-developed with Dr. Mah. It is hoped that future studies will associate real-time physiological features with tumor and CTC profiles for intelligent drug selection.
Clinical Trials
- Recruiting Molecular Analysis of Thoracic Malignancies
- Not Recruiting Molecular Analysis of Breast Cancer
- Not Recruiting Factors Influencing Decision-Making About the Use of Chemoprevention in Women at Increased Risk for Breast Cancer
- Not Recruiting Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
Publications
- Multiplex molecular analysis of CTCs. Recent Results Cancer Res. 2012: 125-40
- Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One. 2012; (5): e33788
- A pharmacogenomic method for individualized prediction of drug sensitivity. Mol Syst Biol. 2011: 513
- Adipose levels of polybrominated diphenyl ethers and risk of breast cancer. Breast Cancer Res Treat. 2011; (2): 505-11
- Distinctive responsiveness to stromal signaling accompanies histologic grade programming of cancer cells. PLoS One. 2011; (5): e20016
- Characterization of molecular subtypes of Korean breast cancer: an ethnically and clinically distinct population. Int J Oncol. 2010; (1): 51-9
Help
Trial Administration